Insights into the Molecular Mechanisms and Nanoparticle-Based Therapies for Gastric Cancer: A review

Results in Engineering, Journal Year: 2025, Volume and Issue: unknown, P. 104238 - 104238

Published: Feb. 1, 2025

Language: Английский

---

Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 19, 2025

KRAS mutations can cause metabolic reprogramming in ovarian cancer, leading to an increased metastatic capacity. This study investigated the changes induced by cancer and mechanism of action metformin combined with a glutaminase 1 inhibitor (CB-839). KRAS-mutant accounted for 14% cancers. The expression glucose metabolism-related (PFKFB3, HK2, GLUT1, PDK2) glutamine enzymes (GLS1 ASCT2) was elevated cells compared that wild-type cells. had higher aerobic oxidative capacity than did Metformin inhibited proliferation, enzymes, those control Furthermore, it enhanced CB-839 proliferation oxidation greater extent observed Additionally, inhibitory effects NOD-SCID mouse model were significantly stronger drug-alone group. lead metabolism cells, which CB-839.

Language: Английский

---

Unraveling the anoikis-cancer nexus: a bibliometric analysis of research trends and mechanisms

Future Science OA, Journal Year: 2025, Volume and Issue: 11(1)

Published: March 31, 2025

Background Cancer, influenced by genetics and the environment, involves anoikis, a cell death mechanism upon extracellular matrix detachment crucial for metastasis. Understanding this relationship is key therapy. We analyze cancer anoikis trends using bibliometrics.

Language: Английский

---

Successful Management of Acquired von Willebrand Syndrome Associated with Monoclonal Gammopathy of Undetermined Significance After Sotorasib Treatment in a Patient with Non-Small-Cell Lung Carcinoma

Hematology Reports, Journal Year: 2025, Volume and Issue: 17(2), P. 21 - 21

Published: April 16, 2025

Background: This case report investigates the effects of sotorasib treatment in a patient with acquired von Willebrand syndrome (AVWS) associated monoclonal gammopathy undetermined significance (MGUS), who subsequently developed non-small-cell lung carcinoma (NSCLC) KRAS G12C mutation. Case Presentation: The patient, 79-year-old male, presented prolonged history recurrent lower gastrointestinal bleeding attributed to digestive angiodysplasia, which had persisted for over 30 years. AVWS was suspected based on qualitative deficiency factor (VWF), abnormal results VIII activity (FVIII:C), VWF antigen (VWF:Ag), and ristocetin cofactor (VWF:Rco) (40%, 20%, <2.4%, respectively). Further evaluation revealed presence an IgM kappa spike, suggesting MGUS. In 2022, diagnosed NSCLC harboring mutation initiated second-line sotorasib. Notably, one year after initiation therapy, patient’s hemostasis normalized, accompanied by significant improvements levels. multimer electrophoresis demonstrated restoration high-molecular-weight multimers (HMWMs), serum protein no longer detected Conclusion: These were likely attributable indirect bone marrow microenvironment. By inhibiting stromal cells osteoclasts, may have disrupted supportive niche necessary malignant plasma cell survival, resulting reduction spike. Unfortunately, eventually succumbed carcinogenic pleurisy.

Language: Английский

---

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1512 - 1512

Published: April 30, 2025

Colorectal cancer (CRC) is one of the most common cancers worldwide, with KRAS mutations occurring in approximately 40% cases. These drive tumorigenesis through constitutive activation key signaling pathways, such as RAS-RAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR, contributing to therapeutic resistance poor prognosis. Advances molecular biology have led significant breakthroughs, including development G12C inhibitors, sotorasib adagrasib, which shown promise clinical trials. However, their efficacy limited a small subset KRAS-mutant CRC, mechanisms often emerge compensatory pathway activation. Combination strategies, inhibitors anti-EGFR agents, been explored trials like KRYSTAL-1 CodeBreaK 300. Emerging research highlights role tumor microenvironment immune evasion resistance, offering opportunities for novel immunotherapy approaches, neoantigen vaccines adoptive T-cell therapy. Despite these advancements, challenges intratumoral heterogeneity, infiltration, non-G12C remain hurdles. This review provides comprehensive overview mechanisms, current advances challenges, future prospects management CRC.

Language: Английский

---

Assessing the toxicological effects and mechanism of plasticizer exposure on inflammatory bowel disease based on network toxicology and molecular docking

Food and Chemical Toxicology, Journal Year: 2025, Volume and Issue: unknown, P. 115543 - 115543

Published: May 1, 2025

Language: Английский

---

Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: June 3, 2025

Pancreatic cancer is a highly lethal malignancy with limited treatment response. Despite advancements in treatment, systemic chemotherapy remains the primary therapeutic approach for over 80% of patients, no established biomarkers to guide drug selection. Traditional two-dimensional (2D) culture models fail replicate tumor microenvironment, necessitating development more advanced models, such as three-dimensional (3D) organoid models. We 3D cultures using patient-derived conditionally reprogrammed cell (CRC) lines, originally cultured under 2D conditions. These CRC organoids were developed Matrigel-based platform without organoid-specific medium components preserve intrinsic molecular subtypes cells. Morphological, molecular, and sensitivity analyses performed compare clinical responses those their counterparts responses. The retained characteristics, transcriptomic mutational profiles parental tumors displayed distinct morphologies corresponding stages differentiation. Drug response profiling gemcitabine plus nab-paclitaxel (Abraxane) FOLFIRINOX demonstrated that accurately mirrored patient than cultures. Notably, IC50 values generally higher, reflecting structural complexity penetration barriers observed vivo. provide robust pre-clinical evaluation, overcoming limitations Although time- resource-intensive, integrating both platforms enables efficient initial screening validation. This holds promise identifying predictive advancing precision medicine pancreatic treatment.

Language: Английский

---

Clinicopathological Diagnosis and Molecular Research Advances in Invasive Mucinous Adenocarcinoma of the Lung

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(06), P. 198 - 205

Published: Jan. 1, 2025

Language: Английский

---